Evoke Pharma Stock Target
Evok) was reported by hc wainwright & co. Yet analysts are ramping up their growth forecast for the fiscal year 2021.
Wall street stock market & finance report, prediction for the future:
Evoke pharma stock target. 1d 5d 1m 3m 6m ytd 1y 3y all range dropdown. D’onofrio has over 27 years of experience in both large and small pharmaceutical firms. The current price of evoke pharma is the price at which evoke pharma is currently trading.
Buy or sell evoke pharma stock? Prior to founding evoke, mr. Evoke pharma inc (evok) stock is trading at $2.48 as of 1:22 pm on tuesday, mar 16, an increase of $0.07, or 2.9% from the previous closing price of $2.41.
The average evoke pharma stock price prediction forecasts a potential downside of n/a from the current evok share price of $0.74. On average, wall street analysts predict that. Evoke pharma's share price could stay at $10.00 by nov 16, 2021.
Research and ratings by barron's. With a target price of €6.00 there is potential for a 728.729% increase which would. 0.8500 52 week range 4.8000.
18, 2016 at 8:49 a.m. Find the latest evoke pharma, inc. (evok) stock discussion in yahoo finance's forum.
Since then, evok stock has decreased by 46.2% and is now trading at $0.5976. The extremes of the forecast give a target low and a target high price of $9.00 and $9.00 respectively. Evolution of the average target price on evoke pharma, inc.
The stock has traded between $2.31 and $2.63 so far today. On the other hand, evoke pharma's target price is what analysts think the stock is worth or could sell for in the future. Evok's sec filings can be seen here.
The latest price target for evoke pharma ( nasdaq: Average price target from 1 ratings: Is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases.
Evoke did see a strong bump in share price after its fda approval. Share your opinion and gain insight from other stock traders and investors. Get the latest evoke pharma stock price and detailed information including evok news, historical charts and realtime prices.
With 2 buy predictions and 0 sell predictions. The volatility of evoke pharma inc's share price is greater than that of 96.11% us stocks with at least 200 days of trading history. D’onofrio was vice president, business development for victory pharma, a biopharmaceutical company focused on acquiring, developing and marketing products to treat pain and related conditions.
If you're looking for stocks that are quantitatively similar to evoke pharma inc, a group of peers worth examining would be urgn, dvax, eose, ocx, and spce. You'll find the evoke pharma share forecasts, stock quote and buy / sell signals below.according to present data evoke pharma's evok shares and potentially its market environment have been in bearish cycle last 12 months. Evoke pharma (nasdaq:evok) price target and consensus rating how marketbeat calculates price target and consensus rating marketbeat calculates consensus analyst ratings for stocks using the most recent rating from each wall street analyst that has rated a stock within the last twelve months.
Nasdaq analyst research provides analyst research for ratings consensus and a summary of stock price targets. Analysts consensus, targets, ratings and recommendations | nasdaq: The analyst firm set a price target for 10.00 expecting evok to rise to within 12.
43 rows this price target is based on 0 analysts offering 12 month price targets for evoke. Evoke pharma inc () stock market info recommendations: Evoke pharma target price projection evoke pharma's current and average target prices are 0.76 and 10.00, respectively.
The community is currently still undecided about evoke pharma inc. Evoke’s gimoti offering is promising but nothing is guaranteed, and the company only has that one product on offering. However, whether the stock can produce returns on your timeline as an investor is an entirely different matter.
Stock quotes are provided by factset, morningstar and s&p capital iq
Post a Comment for "Evoke Pharma Stock Target"